Seamless Therapeutics, a startup developing a new form of gene editing based on enzymes called recombinases, has struck a partnership with Eli Lilly that could be worth more than $1.12 billion, the company announced Wednesday …
Takeda ‘anticipated’ Medicare negotiations for top seller Entyvio
Incoming Takeda CEO Julie Kim says the drugmaker “anticipated” this week’s selection of Entyvio for Medicare negotiations. But for now, the company isn’t ready to




